Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.

Hwang SH, Wecksler AT, Zhang G, Morisseau C, Nguyen LV, Fu SH, Hammock BD.

Bioorg Med Chem Lett. 2013 Jul 1;23(13):3732-7. doi: 10.1016/j.bmcl.2013.05.011. Epub 2013 May 15.

2.

Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.

Liao J, Hwang SH, Li H, Yang Y, Yang J, Wecksler AT, Liu JY, Hammock BD, Yang GY.

Cancer Lett. 2016 Feb 28;371(2):187-93. doi: 10.1016/j.canlet.2015.11.042. Epub 2015 Dec 9.

4.

Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo.

Liu JY, Park SH, Morisseau C, Hwang SH, Hammock BD, Weiss RH.

Mol Cancer Ther. 2009 Aug;8(8):2193-203. doi: 10.1158/1535-7163.MCT-09-0119. Epub 2009 Aug 11.

5.

Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.

Jiao Y, Xin BT, Zhang Y, Wu J, Lu X, Zheng Y, Tang W, Zhou X.

Eur J Med Chem. 2015 Jan 27;90:170-83. doi: 10.1016/j.ejmech.2014.11.008. Epub 2014 Nov 6.

PMID:
25461318
6.

Design and synthesis of substituted nicotinamides as inhibitors of soluble epoxide hydrolase.

Taylor SJ, Soleymanzadeh F, Eldrup AB, Farrow NA, Muegge I, Kukulka A, Kabcenell AK, De Lombaert S.

Bioorg Med Chem Lett. 2009 Oct 15;19(20):5864-8. doi: 10.1016/j.bmcl.2009.08.074. Epub 2009 Aug 26.

PMID:
19758802
7.

Biological evaluation of a novel sorafenib analogue, t-CUPM.

Wecksler AT, Hwang SH, Liu JY, Wettersten HI, Morisseau C, Wu J, Weiss RH, Hammock BD.

Cancer Chemother Pharmacol. 2015 Jan;75(1):161-71. doi: 10.1007/s00280-014-2626-2. Epub 2014 Nov 21.

8.

Inhibition of soluble epoxide hydrolase by fulvestrant and sulfoxides.

Morisseau C, Pakhomova S, Hwang SH, Newcomer ME, Hammock BD.

Bioorg Med Chem Lett. 2013 Jul 1;23(13):3818-21. doi: 10.1016/j.bmcl.2013.04.083. Epub 2013 May 6.

9.

[Advances in the study of structural modifications of multi-target anticancer drug sorafenib].

Yao JW, Sun W, Chen J, Xu WF.

Yao Xue Xue Bao. 2012 Sep;47(9):1111-9. Review. Chinese.

PMID:
23227538
10.

Design, synthesis and biological activities of sorafenib derivatives as antitumor agents.

Yao J, He Z, Chen J, Sun W, Fang H, Xu W.

Bioorg Med Chem Lett. 2012 Nov 1;22(21):6549-53. doi: 10.1016/j.bmcl.2012.09.031. Epub 2012 Sep 19.

PMID:
23021967
11.

[Synthesis and in vitro cytotoxic activities of sorafenib derivatives].

Wang K, Li Y, Zhang LJ, Yang HZ, Chen XG, Feng ZQ.

Yao Xue Xue Bao. 2014 May;49(5):639-43. Chinese.

PMID:
25151734
12.

Biologically active ester derivatives as potent inhibitors of the soluble epoxide hydrolase.

Kim IH, Nishi K, Kasagami T, Morisseau C, Liu JY, Tsai HJ, Hammock BD.

Bioorg Med Chem Lett. 2012 Sep 15;22(18):5889-92. doi: 10.1016/j.bmcl.2012.07.074. Epub 2012 Aug 2.

13.

Synthesis and in vitro antitumor activities of novel benzyl urea analogues of sorafenib.

Lu CS, Tang K, Li Y, Jin B, Yin DL, Ma C, Chen XG, Huang HH.

Yao Xue Xue Bao. 2013 May;48(5):709-17.

PMID:
23888694
14.

Soluble epoxide hydrolase inhibitory activity of anthraquinone components from Aloe.

Sun YN, Kim JH, Li W, Jo AR, Yan XT, Yang SY, Kim YH.

Bioorg Med Chem. 2015 Oct 15;23(20):6659-65. doi: 10.1016/j.bmc.2015.09.003. Epub 2015 Sep 5.

PMID:
26372074
15.

[Design, synthesis and antitumor activity of sorafenib analogues containing 2-picolinylhydrazide moiety].

Qin AF, Li Y, Song HR, Chen XG, Jin XF, Wang K, Zhang LJ, Huo LC, Feng ZQ.

Yao Xue Xue Bao. 2012 Dec;47(12):1623-9. Chinese.

PMID:
23460968
16.

[Synthesis and biological evaluation of sorafenib thiourea derivatives].

Yang Z, Fang Z, Wang ZX, Wei P.

Yao Xue Xue Bao. 2011 Sep;46(9):1093-7. Chinese.

PMID:
22121780
17.

Attenuation of vascular smooth muscle cell proliferation by 1-cyclohexyl-3-dodecyl urea is independent of soluble epoxide hydrolase inhibition.

Davis BB, Morisseau C, Newman JW, Pedersen TL, Hammock BD, Weiss RH.

J Pharmacol Exp Ther. 2006 Feb;316(2):815-21. Epub 2005 Oct 12.

18.
19.

Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties.

North EJ, Scherman MS, Bruhn DF, Scarborough JS, Maddox MM, Jones V, Grzegorzewicz A, Yang L, Hess T, Morisseau C, Jackson M, McNeil MR, Lee RE.

Bioorg Med Chem. 2013 May 1;21(9):2587-99. doi: 10.1016/j.bmc.2013.02.028. Epub 2013 Feb 26.

20.

Design, synthesis and evaluation of non-urea inhibitors of soluble epoxide hydrolase.

Pecic S, Deng SX, Morisseau C, Hammock BD, Landry DW.

Bioorg Med Chem Lett. 2012 Jan 1;22(1):601-5. doi: 10.1016/j.bmcl.2011.10.074. Epub 2011 Oct 28.

Supplemental Content

Support Center